$ACHN News
Last published 6y ago
- 6y agoACHNNew patent granted for: Amino Compounds for Treatment of Medical DisordersUS Patent Applications (USPTO)
- 6y agoACHNNew patent application published for: Therapeutic Regimens for Treatment of Paroxysmal Nocturnal HemoglobinuriaUS Patent Applications (USPTO)
- 6y agoCNSPBCRXCLVSACHN+1Global Glioblastoma Multiforme Drugs Market Projected Could Reach $1.4 Billion By 2025PR NewswireBrain and other nervous system cancers are the 10th leading cause of death for men and women. The global Glioblastoma multiforme (GBM) drugs market...
- 6y agoACHNAchillion Shareholders Approve Agreement to be Acquired by AlexionGlobeNewswireBLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
- 6y agoACHNAchillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology MeetingGlobeNewswire– 2.4 g/dL mean increase in hemoglobin at 24 weeks –– Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis –- Completed End of Phase 2 Meeting; Phase 3 Trial...
- 6y agoSRCIACHNARTXMoore Kuehn, PLLC Encourages Investors of SRC Energy, Inc. (SRCI), Achillion Pharmaceuticals, Inc. (ACHN), and Arotech Corporation (ARTX) to Contact FirmPR NewswireMoore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims involving the directors...
- 6y agoACHNEuropean Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 InhibitorGlobeNewswireBLUE BELL, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
- 7y agoACHNAchillion Announces Clearance of Investigational New Drug Application for ACH-5228GlobeNewswireBLUE BELL, Pa., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
- 7y agoACHNAchillion Announces Data Presentations at the 61st American Society of Hematology Annual MeetingGlobeNewswireBLUE BELL, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
- 7y agoALXNACHNAlexion to Acquire AchillionBusiness WireBOSTON & BLUE BELL, Pa.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) today announced that they have entered into a definitive agreement for Alexion to acquire Achillion, a clinical-stage biopharmaceutical company focused on the development of oral small molecule Factor D inhibitors to treat people with complement alternative pathwa ...
- 7y agoACHNAchillion to Present at the 2019 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewswireBLUE BELL, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
- 7y agoACHNAchillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal HemoglobinuriaGlobeNewswire– Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 –– Initiation of Phase 3 planned for early 2020 – BLUE BELL, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Achillion...
- 7y agoACHNAchillion to Present at the Baird 2019 Global Healthcare ConferenceGlobeNewswireBLUE BELL, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
- 13y agoACHNZeldes Haeggquist & Eck, LLP Announces Investigation of Achillion Pharmaceuticals, Inc.Business WireSAN DIEGO--(BUSINESS WIRE)--Zeldes Haeggquist & Eck, LLP, a shareholder and consumer rights litigation firm, has commenced an investigation into whether certain officers and directors at Achillion Pharmaceuticals, Inc. (“Achillion” or the “Company”), breached their fiduciary duties to shareholders.
- 13y agoACHNGlancy Binkow & Goldberg LLP Encourages Investors of Achillion Pharmaceuticals, Inc. with Losses of $250,000 or More to Contact the FirmBusiness WireLOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Achillion Pharmaceuticals, Inc. (“Achillion” or the “Company”) (NASDAQ:ACHN) concerning possible violations of federal securities laws. Investors with losses of $250,000 or more are encouraged to contact the firm for more information.
- 13y agoACHNWolf Haldenstein Announces Investigation of Achillion Pharmaceuticals Inc.Business WireNEW YORK--(BUSINESS WIRE)--The law firm of Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating potential federal securities claims against Achillion Pharmaceuticals Inc. (“Achilion” or “Company”) (NASDAQ GS:ACHN) and certain of its officers and directors in connection with allegations that the Company made materially false and misleading statements regarding Company’s expe ...
- 14y agoACHNWTRBMTCCCG+11Emerald Holds Annual Groundhog Day Investment ForumBusiness WireLANCASTER, Pa.--(BUSINESS WIRE)--Emerald Asset Management will hold its Nineteenth Annual Emerald Groundhog Day Investment Forum on Tuesday, February 7, 2012 at the Radisson Plaza-Warwick Hotel in Philadelphia. “Energy and passion are hallmarks of the Emerald Groundhog Day Investment Forum,” said Emerald Founder and CEO, Joseph E. Besecker. “The Forum provides a venue to discuss key challenges and ...